AEON Biopharma (AEON) Stock Statistics & Valuation Metrics

AEON Biopharma has a market cap or net worth of $12.71M. The enterprise value is $16.43M.

AEON Biopharma has 12,105,902 shares outstanding. The number of shares has decreased by -2.65% in one year.

AEON Biopharma’s return on equity (ROE) is -1.47 and return on invested capital (ROIC) is -670.45%.

The current PE Ratio of AEON Biopharma is 0.2. AEON Biopharma’s PEG ratio is -0.00030.

In the last 12 months, AEON Biopharma had revenue of 0.00 and earned 42.01M in profits. Earnings per share was 77.74.

In the last 12 months, operating cash flow was -13.22M and capital expenditures -4.00K, giving a free cash flow of -13.22M billion.

AEON Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

AEON Biopharma upcoming earnings date is Apr 1, 2026, Before Open (Confirmed).

AEON Biopharma as a current ratio of 0.11, with Debt / Equity ratio of -90.62%

In the past 12 months, AEON Biopharma has paid 0.00 in taxes.

AEON Biopharma EV to EBITDA ratio is -1.22, with an EV/FCF ratio of -1.67.

AEON Biopharma has $5.93M in cash and marketable securities with $18.25M in debt, giving a net cash position of -$12.33M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for AEON Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―